Therapy News and Research

RSS

Study reveals pivotal role of the circadian clock in enhancing checkpoint inhibitor cancer therapy

A multidisciplinary research team at the University of California, Irvine has revealed that the circadian clock – the biological pacemaker that governs daily rhythms in physiological processes, including immune functions – can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.

28 May 2024

New subset of T cells may enhance cancer immunotherapy

A team of cancer researchers, led by the University of Houston, has discovered a new subset of T cells that may improve the outcome for patients treated with T-cell therapies.

28 May 2024

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Semaglutide and its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice.

28 May 2024

Researchers develop mathematical model to predict effective dosage range of cancer treatment

Cancer poses significant challenges due to the development of resistance and the likelihood of relapse. Resistance may arise from permanent genetic changes in cancer cells or non-genetic alterations in cancer cell behavior induced by treatment.

28 May 2024

New help for dealing with aggression in people with dementia

Caring for older adults with dementia is stressful, especially when they become physically or verbally aggressive, wander away from home, develop paranoia or hallucinations, engage in inappropriate or repetitive behaviors, or refuse to let caregivers help them.

28 May 2024

Taking semaglutide once weekly may lower the chances of kidney disease, says study

The effects of semaglutide (administered once weekly) on the outcomes of kidney disease.

28 May 2024

Changing the landscape of R&D to build clinical success from the ground up

In this interview, NewsMedical talks to Amanda Jones at Revvity about the strategies and solutions available to revolutionize the landscape of R&D in clinical research.

From Revvity 28 May 2024

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director. Rafiq brings extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.

28 May 2024

New frontiers in medicine: COVID-19 lessons push for multidisciplinary collaboration

Researchers highlight the need for multidisciplinary collaboration in medicine, especially in addressing transmissible illnesses, precision medicine, and data science, as learned from the COVID-19 pandemic.

28 May 2024

Study links high sugar intake to lower childhood asthma risk, while fat, magnesium, and vitamin D increase it

Using Mendelian Randomization, researchers found that high sugar intake may lower childhood asthma risk, while high fat, magnesium, and vitamin D intake increase it.

27 May 2024

New antibody therapy shows promise in combating kidney transplant rejection

Antibody-mediated rejection (AMR) is one of the most common causes of kidney transplant failure. To date, however, no treatment has proven effective in combating this complication in the long term.

27 May 2024

Personalized phage therapy successfully treats antibiotic-resistant infections in animals

A new study demonstrates an advance in treating antibiotic-resistant infections in animals through personalized phage therapy.

27 May 2024

$Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy$

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

27 May 2024

Mediterranean diet cuts environmental impact and improves metabolic health, study finds

Researchers found that a Mediterranean diet with reduced energy intake significantly reduced environmental impacts, such as acidification, eutrophication, and land use, in individuals with metabolic syndrome. Caloric reduction and diet adherence were key factors mediating these benefits.

27 May 2024

Running therapy matches antidepressants for mental health, surpasses for physical benefits

Researchers found that while both antidepressants and group running therapy effectively improved mental health in patients with anxiety and depression, running therapy had significantly better outcomes for physical health indicators.

26 May 2024

SELECT trial shows semaglutide reduces kidney decline in obese patients

The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.

25 May 2024

AI-based body composition analysis predicts lung cancer treatment outcomes

Tafadzwa Chaunzwa, MD, a researcher in the Artificial Intelligence in Medicine (AIM) Program at Mass General Brigham and a senior resident physician at the Harvard Radiation Oncology Program, is the lead author of a paper published in JAMA Oncology.

24 May 2024

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent.

24 May 2024

Evaluating systemic thrombolysis for acute portal vein thrombosis in cirrhotic patients

The prevalence of Portal Vein Thrombosis (PVT) varies significantly at different stages of liver disease: 10% in compensated patients, 17% in decompensated patients, 9% in those with acute decompensated cirrhosis, and 2-26% in post-liver transplant patients.

24 May 2024

Two new studies offer insights into the molecular biology of neuropsychiatric disease

Working under the umbrella of the PsychENCODE Consortium, the mental health research project established in 2015 by the National Institutes of Health, a team of Mount Sinai scientists has uncovered important new insights into the molecular biology of neuropsychiatric disease through two new studies published in a special issue of Science on Friday, May 24.

24 May 2024

Therapy News and Research

Study reveals pivotal role of the circadian clock in enhancing checkpoint inhibitor cancer therapy

New subset of T cells may enhance cancer immunotherapy

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Researchers develop mathematical model to predict effective dosage range of cancer treatment

New help for dealing with aggression in people with dementia

Taking semaglutide once weekly may lower the chances of kidney disease, says study

Changing the landscape of R&D to build clinical success from the ground up

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

New frontiers in medicine: COVID-19 lessons push for multidisciplinary collaboration

Study links high sugar intake to lower childhood asthma risk, while fat, magnesium, and vitamin D increase it

New antibody therapy shows promise in combating kidney transplant rejection

Personalized phage therapy successfully treats antibiotic-resistant infections in animals

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

Mediterranean diet cuts environmental impact and improves metabolic health, study finds

Running therapy matches antidepressants for mental health, surpasses for physical benefits

SELECT trial shows semaglutide reduces kidney decline in obese patients

AI-based body composition analysis predicts lung cancer treatment outcomes

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

Evaluating systemic thrombolysis for acute portal vein thrombosis in cirrhotic patients

Two new studies offer insights into the molecular biology of neuropsychiatric disease

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News